Reference Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Ref Type
PMID
Authors Jian Li Campian, Vaishali Kapoor, Kaylan Griffith, Anita Mahadevan, Andrea Collins, Sukrutha Thotala, Arijita Jash, Tong Hu, Byung Ha Lee, Donghoon Choi, Se Hwan Yang, Dennis Hallahan, Milan G Chheda, Dinesh Thotala
Title Effect of a novel long-acting interleukin-7 agonist, NT-I7, on survival in mouse models of glioma.
URL https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_suppl.e13516
Abstract Text Journal of Clinical Oncology 37, no. 15_suppl, Abs nr: e13516

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Treatment Approach
Gene Name Source Synonyms Protein Domains Gene Description Gene Role
Therapy Name Drugs Efficacy Evidence Clinical Trials
NT-I7 NT-I7 0 3
Drug Name Trade Name Synonyms Drug Classes Drug Description
NT-I7 GX-I7|rhIL-7-hyFc|IL-7-hyFc|Efineptakin alfa|Hyleukin NT-I7 is a fusion protein comprised of a recombinant interleukin-7 (IL-7) linked to a hybrid immunoglobulin Fc region, which potentially has increased stability and enhances anti-tumor immune response (Journal of Clinical Oncology 37, no. 15_suppl, Abs nr: e13516).
Gene Variant Impact Protein Effect Variant Description Associated with drug Resistance
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References